The MathWorks

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

A new scientific event in Gothenburg

Life Science Sweden is holding an event in Gothenburg for the first time.

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

KI-bolag får stöd av Michael J. Fox Foundation

Svenska Umecrine Cognition har fått ett anslag från The Michael J. Fox Foundation för att utvärdera bolagets läkemedelskandidat golexanolon som behandling för P...

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Mercodia AB